<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38862591</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.</ArticleTitle><Pagination><StartPage>13462</StartPage><MedlinePgn>13462</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13462</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-64260-9</ELocationID><Abstract><AbstractText>There have been 774,075,242 cases of COVID-19 and 7,012,986 deaths worldwide as of January 2024. In the early stages of the pandemic, there was an urgent need to reduce the severity of the disease and prevent the need for hospitalization to avoid stress on healthcare systems worldwide. The repurposing of drugs to prevent clinical deterioration of COVID-19 patients was trialed in many studies using many different drugs. Fluvoxamine (an SSRI and sigma-1 receptor agonist) was initially identified to potentially provide beneficial effects in COVID-19-infected patients, preventing clinical deterioration and the need for hospitalization. Fourteen clinical studies have been carried out to date, with seven of those being randomized placebo-controlled studies. This systematic review and meta-analysis covers the literature from the outbreak of SARS-CoV-2 in late 2019 until January 2024. Search terms related to fluvoxamine, such as its trade names and chemical names, along with words related to COVID-19, such as SARS-CoV-2 and coronavirus, were used in literature databases including PubMed, Google Scholar, Scopus, and the ClinicalTrials.gov database from NIH, to identify the trials used in the subsequent analysis. Clinical deterioration and death data were extracted from these studies where available and used in the meta-analysis. A total of 7153 patients were studied across 14 studies (both open-label and double-blind placebo-controlled). 681 out of 3553 (19.17%) in the standard care group and 255 out of 3600 (7.08%) in the fluvoxamine-treated group experienced clinical deterioration. The estimated average log odds ratio was 1.087 (95% CI 0.200 to 1.973), which differed significantly from zero (z&#x2009;=&#x2009;2.402, p&#x2009;=&#x2009;0.016). The seven placebo-controlled studies resulted in a log odds ratio of 0.359 (95% CI 0.1111 to 0.5294), which differed significantly from zero (z&#x2009;=&#x2009;3.103, p&#x2009;=&#x2009;0.002). The results of this study identified fluvoxamine as effective in preventing clinical deterioration, and subgrouping analysis suggests that earlier treatment with a dose of 200&#xa0;mg or above provides the best outcomes. We hope the outcomes of this study can help design future studies into respiratory viral infections and potentially improve clinical outcomes.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prasanth</LastName><ForeName>Mani Iyer</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Natural Products for Neuroprotection and Anti-Ageing (Neur-Age Natura) Research Unit, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wannigama</LastName><ForeName>Dhammika Leshan</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Thai Red Cross Society, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yamagata Prefectural University of Health Sciences, Kamiyanagi, Yamagata, 990-2212, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pathogen Hunter's Research Collaborative Team, Department of Infectious Diseases and Infection Control, Yamagata Prefectural Central Hospital, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiersen</LastName><ForeName>Angela Michelle</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thitilertdecha</LastName><ForeName>Premrutai</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Siriraj Research Group in Immunobiology and Therapeutic Sciences, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasansuklab</LastName><ForeName>Anchalee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Natural Products for Neuroprotection and Anti-Ageing (Neur-Age Natura) Research Unit, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Public Health Sciences, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tencomnao</LastName><ForeName>Tewin</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Natural Products for Neuroprotection and Anti-Ageing (Neur-Age Natura) Research Unit, Chulalongkorn University, Bangkok, 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brimson</LastName><ForeName>Sirikalaya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brimson</LastName><ForeName>James Michael</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Natural Products for Neuroprotection and Anti-Ageing (Neur-Age Natura) Research Unit, Chulalongkorn University, Bangkok, 10330, Thailand. Jamesmichael.b@chula.ac.th.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research, Innovation and International Affairs, Faculty of Allied Health Sciences, Chulalongkorn University, 154 Rama 1 Road, Pathumwan, Wang Mai, Bangkok, 10330, Thailand. Jamesmichael.b@chula.ac.th.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Sys_66_007_3700_001</GrantID><Agency>the Ratchadaprisk Sompoch Endowment Fund (2023) Chulalongkorn University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Selective Serotonin Reuptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Sci Rep. 2024 Jul 22;14(1):16774. doi: 10.1038/s41598-024-67936-4</RefSource><PMID Version="1">39039269</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016666" MajorTopicYN="Y">Fluvoxamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075902" MajorTopicYN="N">Clinical Deterioration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(E)&#x2010;5&#x2010;methoxy&#x2010;1&#x2010;[4&#x2010;(trifluoromethyl)phenyl]pentan&#x2010;1&#x2010;one O&#x2010;2&#x2010;aminoethyl oxime)</Keyword><Keyword MajorTopicYN="N">Antidepressant</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Drug repurposing</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Sigma-1 receptor (&#x3c3;1R)</Keyword></KeywordList><CoiStatement>AMR is listed as an inventor on a patent application related to methods of treating COVID-19 (including Sigma1 agonists and specifically fluvoxamine), which was filed by Washington University in St. Louis. No other author declares any potential conflict of interest or competing financial or non-financial interest in relation to the manuscript. AMR is listed on a patent application that includes the use of &#x3c3;1R agonists for the treatment of COVID-19. No other authors have any conflicts to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>12</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>11</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38862591</ArticleId><ArticleId IdType="pmc">PMC11166997</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-64260-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-64260-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol.5, 536&#x2013;544, 10.1038/s41564-020-0695-z (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>World-Health-Organization. WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19), https://data.who.int/dashboards/covid19/deaths (2023).</Citation></Reference><Reference><Citation>Feehan, J. &amp; Apostolopoulos, V. Is COVID-19 the worst pandemic?. Maturitas149, 56&#x2013;58. 10.1016/j.maturitas.2021.02.001 (2021). 10.1016/j.maturitas.2021.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2021.02.001</ArticleId><ArticleId IdType="pmc">PMC7866842</ArticleId><ArticleId IdType="pubmed">33579552</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryasa, I. W., Rodr&#xed;guez-G&#xe1;mez, M. &amp; Koldoris, T. The COVID-19 pandemic. Int. J. Health Sci.5 (2021).</Citation></Reference><Reference><Citation>Wannigama, D. L. et al. Tracing the new SARS-CoV-2 variant BA. 2.86 in the community through wastewater surveillance in Bangkok, Thailand. Lancet Infect. Dis.23, e464&#x2013;e466 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37813112</ArticleId></ArticleIdList></Reference><Reference><Citation>Rad, S. A. H., Wannigama, D. L., Hirankarn, N. &amp; McLellan, A. D. The impact of non-synonymous mutations on miRNA binding sites within the SARS-CoV-2 NSP3 and NSP4 genes. Sci. Rep.13, 16945 (2023). 10.1038/s41598-023-44219-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-44219-y</ArticleId><ArticleId IdType="pmc">PMC10560223</ArticleId><ArticleId IdType="pubmed">37805621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannigama, D. L. et al. COVID-19 monitoring with sparse sampling of sewered and non-sewered wastewater in urban and rural communities. Iscience26, 107019 (2023). 10.1016/j.isci.2023.107019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107019</ArticleId><ArticleId IdType="pmc">PMC10250052</ArticleId><ArticleId IdType="pubmed">37351501</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, R. L. et al. Pathophysiology, diagnosis, and management of neuroinflammation in covid-19. bmj382 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37595965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto, K. Overview of the potential use of fluvoxamine for COVID-19 and long COVID. Discov. Mental Health3, 9 (2023).10.1007/s44192-023-00036-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44192-023-00036-3</ArticleId><ArticleId IdType="pmc">PMC10029802</ArticleId><ArticleId IdType="pubmed">36968793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, T.-B. et al. Neuroimmunological effect of vitamin D on neuropsychiatric Long COVID syndrome: A review. Nutrients15, 3802 (2023). 10.3390/nu15173802</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15173802</ArticleId><ArticleId IdType="pmc">PMC10490318</ArticleId><ArticleId IdType="pubmed">37686834</ArticleId></ArticleIdList></Reference><Reference><Citation>Omori, I. M. et al. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst. Rev.10.1002/14651858.CD006114.pub2 (2010). 10.1002/14651858.CD006114.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD006114.pub2</ArticleId><ArticleId IdType="pmc">PMC4171125</ArticleId><ArticleId IdType="pubmed">20238342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze, E. J. et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA324, 2292&#x2013;2300. 10.1001/jama.2020.22760 (2020). 10.1001/jama.2020.22760</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22760</ArticleId><ArticleId IdType="pmc">PMC7662481</ArticleId><ArticleId IdType="pubmed">33180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto, Y., Suzuki, T. &amp; Hashimoto, K. Mechanisms of action of fluvoxamine for COVID-19: A historical review. Mol. Psychiatry27, 1898&#x2013;1907 (2022). 10.1038/s41380-021-01432-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01432-3</ArticleId><ArticleId IdType="pmc">PMC8739627</ArticleId><ArticleId IdType="pubmed">34997196</ArticleId></ArticleIdList></Reference><Reference><Citation>Friesland, M., Mingorance, L., Chung, J., Chisari, F. V. &amp; Gastaminza, P. Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J. Virol.87, 6377&#x2013;6390 (2013). 10.1128/JVI.03557-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03557-12</ArticleId><ArticleId IdType="pmc">PMC3648129</ArticleId><ArticleId IdType="pubmed">23536676</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasallo, C. &amp; Gastaminza, P. Cellular stress responses in hepatitis C virus infection: Mastering a two-edged sword. Virus Res.209, 100&#x2013;117 (2015). 10.1016/j.virusres.2015.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2015.03.013</ArticleId><ArticleId IdType="pubmed">25836277</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature583, 459&#x2013;468 (2020). 10.1038/s41586-020-2286-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa, M. et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: A positron emission tomography study using [11C] SA4503. Biol. Psychiatry62, 878&#x2013;883 (2007). 10.1016/j.biopsych.2007.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2007.04.001</ArticleId><ArticleId IdType="pubmed">17662961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozonoff, A. et al. Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: Results from the IMPACC study. Nat. Commun.15, 216. 10.1038/s41467-023-44090-5 (2024). 10.1038/s41467-023-44090-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44090-5</ArticleId><ArticleId IdType="pmc">PMC10764789</ArticleId><ArticleId IdType="pubmed">38172101</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff, D. et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: A systematic review. JAMA Netw. Open4, e2128568&#x2013;e2128568 (2021). 10.1001/jamanetworkopen.2021.28568</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles, V. G. et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med.383, 590&#x2013;592 (2020). 10.1056/NEJMc2011400</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhea, E. M. et al. The S1 protein of SARS-CoV-2 crosses the blood&#x2013;brain barrier in mice. Nat. Neurosci.24, 368&#x2013;378 (2021). 10.1038/s41593-020-00771-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00771-8</ArticleId><ArticleId IdType="pmc">PMC8793077</ArticleId><ArticleId IdType="pubmed">33328624</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis, G. et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial. Lancet Glob. Health10, e42&#x2013;e51. 10.1016/s2214-109x(21)00448-4 (2022). 10.1016/s2214-109x(21)00448-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2214-109x(21)00448-4</ArticleId><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante, C. T. et al. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. N. Engl. J. Med.387, 599&#x2013;610. 10.1056/NEJMoa2201662 (2022). 10.1056/NEJMoa2201662</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2201662</ArticleId><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy, M. W. et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: A randomized clinical trial. JAMA329, 296&#x2013;305. 10.1001/jama.2022.24100 (2023). 10.1001/jama.2022.24100</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.24100</ArticleId><ArticleId IdType="pmc">PMC9857647</ArticleId><ArticleId IdType="pubmed">36633838</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo, H. et al. Fluvoxamine treatment of patients with symptomatic COVID-19 in a community treatment center: A Preliminary result of randomized controlled trial. Infect. Chemother.54, 102&#x2013;113. 10.3947/ic.2021.0142 (2022). 10.3947/ic.2021.0142</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2021.0142</ArticleId><ArticleId IdType="pmc">PMC8987178</ArticleId><ArticleId IdType="pubmed">35384422</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart, T. G. et al. Higher-Dose fluvoxamine and time to sustained recovery in outpatients with COVID-19: The ACTIV-6 randomized clinical trial. JAMA330, 2354&#x2013;2363. 10.1001/jama.2023.23363 (2023). 10.1001/jama.2023.23363</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.23363</ArticleId><ArticleId IdType="pmc">PMC10656670</ArticleId><ArticleId IdType="pubmed">37976072</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiersen, A. M. et al. The STOP COVID 2 Study: Fluvoxamine vs placebo for outpatients with symptomatic COVID-19, a fully remote randomized controlled trial. Open Forum Infect. Dis.10, ofad419, 10.1093/ofid/ofad419 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10445518</ArticleId><ArticleId IdType="pubmed">37622035</ArticleId></ArticleIdList></Reference><Reference><Citation>Calusic, M. et al. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls. Br. J. Clin. Pharmacol.88, 2065&#x2013;2073. 10.1111/bcp.15126 (2022). 10.1111/bcp.15126</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15126</ArticleId><ArticleId IdType="pmc">PMC8653355</ArticleId><ArticleId IdType="pubmed">34719789</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda, E. et al. Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study. Front. Pharmacol.13, 1054644. 10.3389/fphar.2022.1054644 (2022). 10.3389/fphar.2022.1054644</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1054644</ArticleId><ArticleId IdType="pmc">PMC9748291</ArticleId><ArticleId IdType="pubmed">36532727</ArticleId></ArticleIdList></Reference><Reference><Citation>Seftel, D. &amp; Boulware, D. R. Prospective Cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect. Dis.8, ofab050. 10.1093/ofid/ofab050 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7888564</ArticleId><ArticleId IdType="pubmed">33623808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirenga, B. J. et al. Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: A prospective interventional open-label cohort study. Mol. Psychiatry10.1038/s41380-023-02004-3 (2023). 10.1038/s41380-023-02004-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-023-02004-3</ArticleId><ArticleId IdType="pmc">PMC9982784</ArticleId><ArticleId IdType="pubmed">36869228</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiakalos, A., Ziakas, P. D., Polyzou, E., Schinas, G. &amp; Akinosoglou, K. Early fluvoxamine reduces the risk for clinical deterioration in symptomatic outpatients with COVID-19: A real-world, retrospective, before-after analysis. Microorganisms.10.3390/microorganisms11082073 (2023). 10.3390/microorganisms11082073</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11082073</ArticleId><ArticleId IdType="pmc">PMC10459506</ArticleId><ArticleId IdType="pubmed">37630633</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannigama, D. L., et al. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: A randomized clinical trial. EClinicalMedicine70 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10955208</ArticleId><ArticleId IdType="pubmed">38516100</ArticleId></ArticleIdList></Reference><Reference><Citation>Siripongboonsitti, T. et al. Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study). Int. J. Infect. Dis.134, 211&#x2013;219. 10.1016/j.ijid.2023.06.018 (2023). 10.1016/j.ijid.2023.06.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.06.018</ArticleId><ArticleId IdType="pubmed">37393041</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskotsky, T. et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw. Open4, e2133090. 10.1001/jamanetworkopen.2021.33090 (2021). 10.1001/jamanetworkopen.2021.33090</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.33090</ArticleId><ArticleId IdType="pmc">PMC8593759</ArticleId><ArticleId IdType="pubmed">34779847</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimson, J. M. et al. The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data. Sci. Rep.11, 1&#x2013;11 (2021). 10.1038/s41598-020-80045-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80045-2</ArticleId><ArticleId IdType="pmc">PMC7803732</ArticleId><ArticleId IdType="pubmed">33436817</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad, A. R. et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clin. Trials17, 1&#x2013;12 (1996). 10.1016/0197-2456(95)00134-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(95)00134-4</ArticleId><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>The Jamovi project. v. Jamovi (Version 2.3) (https://www.jamovi.org, 2023).</Citation></Reference><Reference><Citation>Viechtbauer, W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J. Educ. Behav. Statistics30, 261&#x2013;293 (2005).10.3102/10769986030003261</Citation><ArticleIdList><ArticleId IdType="doi">10.3102/10769986030003261</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiersen, A. M., Zorumski, C. F. &amp; Lenze, E. J. Fluvoxamine and long COVID: Post-acute recovery. Rev. Med. Virol.34(4), e2557. 10.1002/rmv.2557 (2024). 10.1002/rmv.2557</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2557</ArticleId><ArticleId IdType="pubmed">38825753</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante, C. T. et al. Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up. medRxiv. 10.1101/2022.12.21.22283753 (2022).</Citation></Reference><Reference><Citation>Farahani, R. H., Ajam, A. &amp; Naeini, A. R. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial. BMC Infect. Dis.23, 197. 10.1186/s12879-023-08172-5 (2023). 10.1186/s12879-023-08172-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08172-5</ArticleId><ArticleId IdType="pmc">PMC10064948</ArticleId><ArticleId IdType="pubmed">37003990</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidky, H. et al. Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19. Comput. Struct. Biotechnol. J.24, 115&#x2013;125. 10.1016/j.csbj.2023.12.045 (2024). 10.1016/j.csbj.2023.12.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2023.12.045</ArticleId><ArticleId IdType="pmc">PMC10839808</ArticleId><ArticleId IdType="pubmed">38318198</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto, K. Overview of the potential use of fluvoxamine for COVID-19 and long COVID. Discov. Ment. Health3, 9. 10.1007/s44192-023-00036-3 (2023). 10.1007/s44192-023-00036-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44192-023-00036-3</ArticleId><ArticleId IdType="pmc">PMC10029802</ArticleId><ArticleId IdType="pubmed">36968793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishima, T., Fujita, Y. &amp; Hashimoto, K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur. J. Pharmacol.727, 167&#x2013;173 (2014). 10.1016/j.ejphar.2014.01.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2014.01.064</ArticleId><ArticleId IdType="pubmed">24508523</ArticleId></ArticleIdList></Reference><Reference><Citation>Khani, E. &amp; Entezari-Maleki, T. Fluvoxamine and long COVID-19: A new role for sigma-1 receptor (S1R) agonists. Mol. Psychiatry27, 3562&#x2013;3562 (2022). 10.1038/s41380-022-01545-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01545-3</ArticleId><ArticleId IdType="pmc">PMC8985056</ArticleId><ArticleId IdType="pubmed">35388182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto, Y., Suzuki, T. &amp; Hashimoto, K. Comments to &#x201c;Fluvoxamine and long COVID-19: A new role for sigma-1 receptor (S1R) agonists&#x201d; by Khani and Entezari-Maleki. Mol. Psychiatry27, 3563&#x2013;3564 (2022). 10.1038/s41380-022-01546-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01546-2</ArticleId><ArticleId IdType="pmc">PMC8985059</ArticleId><ArticleId IdType="pubmed">35388183</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenton, C. &amp; Lee, A. Antidepressants with anti-inflammatory properties may be useful in long COVID depression. Drugs Therapy Perspect.39, 65&#x2013;70 (2023).10.1007/s40267-022-00975-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40267-022-00975-x</ArticleId><ArticleId IdType="pmc">PMC9742030</ArticleId><ArticleId IdType="pubmed">36532316</ArticleId></ArticleIdList></Reference><Reference><Citation>French, G. et al. Impact of hospital strain on excess deaths during the COVID-19 pandemic&#x2014;United States, July 2020&#x2013;July 2021. Morb. Mortal. Wkly. Rep.70, 1613 (2021).10.15585/mmwr.mm7046a5</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7046a5</ArticleId><ArticleId IdType="pmc">PMC8601411</ArticleId><ArticleId IdType="pubmed">34793414</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodebaugh, T. L. et al. Acute symptoms of mild to moderate COVID-19 are highly heterogeneous across individuals and over time. Open Forum Infect Dis8, ofab090, 10.1093/ofid/ofab090 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989225</ArticleId><ArticleId IdType="pubmed">33796601</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin, D. O. et al. The importance of understanding the stages of COVID-19 in treatment and trials. AIDS Rev.23 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33556957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannigama, D. L. &amp; Jacquet, A. NOD2-dependent BCG-induced trained immunity: A way to regulate innate responses to SARS-CoV2?. Int. J. Infect. Dis.101, 52&#x2013;55 (2020). 10.1016/j.ijid.2020.09.1429</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.1429</ArticleId><ArticleId IdType="pmc">PMC7832069</ArticleId><ArticleId IdType="pubmed">32980554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay, M. Z., Poh, C. M., R&#xe9;nia, L., MacAry, P. A. &amp; Ng, L. F. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol.20, 363&#x2013;374 (2020). 10.1038/s41577-020-0311-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0311-8</ArticleId><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad, M. &amp; Martin, J. C. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol.20, 355&#x2013;362 (2020). 10.1038/s41577-020-0331-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0331-4</ArticleId><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. &amp; Topol, E. J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol.21, 133&#x2013;146 (2023). 10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Batool, S. et al. Efficacy and safety of favipiravir in treating COVID-19 patients: A meta-analysis of randomized control trials. Cureus15 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9918851</ArticleId><ArticleId IdType="pubmed">36788824</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah, P. L. et al. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): A multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. Lancet Respir. Med.11, 415&#x2013;424 (2023). 10.1016/S2213-2600(22)00412-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00412-X</ArticleId><ArticleId IdType="pmc">PMC9891737</ArticleId><ArticleId IdType="pubmed">36528039</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoops, K. et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol.6, e226 (2008). 10.1371/journal.pbio.0060226</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0060226</ArticleId><ArticleId IdType="pmc">PMC2535663</ArticleId><ArticleId IdType="pubmed">18798692</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier, H. J. et al. Infectious bronchitis virus generates spherules from zippered endoplasmic reticulum membranes. MBio4 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812713</ArticleId><ArticleId IdType="pubmed">24149513</ArticleId></ArticleIdList></Reference><Reference><Citation>Reggiori, F. et al. Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-derived vesicles exporting short-lived ERAD regulators, for replication. Cell Host Microbe7, 500&#x2013;508 (2010). 10.1016/j.chom.2010.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.05.013</ArticleId><ArticleId IdType="pmc">PMC7103375</ArticleId><ArticleId IdType="pubmed">20542253</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung, T. S. &amp; Liu, D. X. Coronavirus infection, ER stress, apoptosis and innate immunity. Front. Microbiol.5, 296 (2014). 10.3389/fmicb.2014.00296</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2014.00296</ArticleId><ArticleId IdType="pmc">PMC4060729</ArticleId><ArticleId IdType="pubmed">24987391</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung, T. S. &amp; Liu, D. X. The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy induction in cells infected with coronavirus infectious bronchitis virus. Virology533, 34&#x2013;44. 10.1016/j.virol.2019.05.002 (2019). 10.1016/j.virol.2019.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2019.05.002</ArticleId><ArticleId IdType="pmc">PMC7112053</ArticleId><ArticleId IdType="pubmed">31082732</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh, K. K., Chaubey, G., Chen, J. Y. &amp; Suravajhala, P. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. Am. J. Physiol. Cell Physiol. (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381712</ArticleId><ArticleId IdType="pubmed">32510973</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti, P., Ilamathi, H. S., Todkar, K. &amp; Germain, M. Mitochondria targeted viral replication and survival strategies&#x2014;Prospective on SARS-CoV-2. Front. Pharmacol.11 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7485471</ArticleId><ArticleId IdType="pubmed">32982760</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, P., Li, W., Xie, J., Hou, Y. &amp; You, C. Cytokine storm induced by SARS-CoV-2. Clin. Chim. Acta (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283076</ArticleId><ArticleId IdType="pubmed">32531256</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen, S. F. &amp; Ho, Y.-C. SARS-CoV-2: a Storm is raging. J. Clin. Investig.130 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190904</ArticleId><ArticleId IdType="pubmed">32217834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen, D. A. et al. Modulation of the sigma-1 receptor&#x2013;IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci. Transl. Med.11, eaau5266. 10.1126/scitranslmed.aau5266 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936250</ArticleId><ArticleId IdType="pubmed">30728287</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;rtter, S., Gr&#xf6;zinger, M., Weigmann, H., R&#xf6;schke, J. &amp; Hiemke, C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin. Pharmacol. Ther.67, 1&#x2013;6 (2000). 10.1067/mcp.2000.104071</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mcp.2000.104071</ArticleId><ArticleId IdType="pubmed">10668847</ArticleId></ArticleIdList></Reference><Reference><Citation>Demisch, K. et al. Melatonin and cortisol increase after fluvoxamine. Br. J. Clin. Pharmacol.22, 620&#x2013;622. 10.1111/j.1365-2125.1986.tb02947.x (1986). 10.1111/j.1365-2125.1986.tb02947.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1986.tb02947.x</ArticleId><ArticleId IdType="pmc">PMC1401188</ArticleId><ArticleId IdType="pubmed">3098271</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon, D. E. et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science (New York, N.Y.)370, eabe9403. 10.1126/science.abe9403 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808408</ArticleId><ArticleId IdType="pubmed">33060197</ArticleId></ArticleIdList></Reference><Reference><Citation>Vela, J. M. Repurposing sigma-1 receptor ligands for COVID-19 therapy? Front. Pharmacol.10.3389/fphar.2020.582310 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7751758</ArticleId><ArticleId IdType="pubmed">33364957</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos, K. I., Sutheesophon, W. &amp; Aw, T. C. Anti-SARS-CoV-2 action of fluvoxamine may be mediated by endothelial nitric oxide synthase. Pharmacopsychiatry55, 57. 10.1055/a-1641-0357 (2022). 10.1055/a-1641-0357</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1641-0357</ArticleId><ArticleId IdType="pubmed">34555857</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos, K. I., Papadopoulou, A. &amp; Aw, T. C. Beauty and the beast: Host microRNA-155 versus SARS-CoV-2. Hum Cell36, 908&#x2013;922. 10.1007/s13577-023-00867-w (2023). 10.1007/s13577-023-00867-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-023-00867-w</ArticleId><ArticleId IdType="pmc">PMC9969954</ArticleId><ArticleId IdType="pubmed">36847920</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos, K. I., Papadopoulou, A. &amp; Aw, T. C. Anexelekto (AXL) no more: microRNA-155 (miR-155) controls the &#x201c;Uncontrolled&#x201d; in SARS-CoV-2. Hum. Cell37, 582&#x2013;592. 10.1007/s13577-024-01041-6 (2024). 10.1007/s13577-024-01041-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-024-01041-6</ArticleId><ArticleId IdType="pubmed">38472734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kugler, N., Klein, K. &amp; Zanger, U. M. MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation. Biochem. Pharmacol.171, 113725. 10.1016/j.bcp.2019.113725 (2020). 10.1016/j.bcp.2019.113725</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2019.113725</ArticleId><ArticleId IdType="pubmed">31758923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. et al. MiR-155 is involved in major depression disorder and antidepressant treatment via targeting SIRT1. Biosci Rep. 10.1042/bsr20181139 (2018).10.1042/bsr20181139</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bsr20181139</ArticleId><ArticleId IdType="pmc">PMC6435510</ArticleId><ArticleId IdType="pubmed">30482883</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos, K. I., Papadopoulou, A. &amp; Aw, T. C. Selective serotonin reuptake inhibitors may influence COVID-19 prognosis through antioxidant and cytoprotective pathways mediated by sigma 1 receptor agonism. Pharmacopsychiatry55, 305&#x2013;306. 10.1055/a-1909-2198 (2022). 10.1055/a-1909-2198</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1909-2198</ArticleId><ArticleId IdType="pubmed">35981550</ArticleId></ArticleIdList></Reference><Reference><Citation>Trkulja, V. Why we should not recommend or offer fluvoxamine to COVID-19 patients?. Eur. J. Clin. Pharmacol.79, 321&#x2013;322. 10.1007/s00228-022-03447-3 (2023). 10.1007/s00228-022-03447-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-022-03447-3</ArticleId><ArticleId IdType="pmc">PMC9780092</ArticleId><ArticleId IdType="pubmed">36550263</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis, G. et al. Oral fluvoxamine with inhaled budesonide for treatment of early-onset COVID-19: A randomized platform trial. Ann. Intern. Med.176, 667&#x2013;675 (2023). 10.7326/M22-3305</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-3305</ArticleId><ArticleId IdType="pmc">PMC10111398</ArticleId><ArticleId IdType="pubmed">37068273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>